Meeker David P 4

What Happened

• David P. Meeker, President, CEO and a director of Rhythm Pharmaceuticals (RYTM), received two equity awards reported on a Form 4 dated 2026-02-13 for transactions on 2026-02-11. The grants consist of 71,900 restricted stock units (RSUs) and 107,850 stock option awards, each shown as acquired at $0.00 on the Form 4 (totaling 179,750 derivative awards).
• These are grants (not open-market purchases or sales). RSUs are contingent rights to receive shares; the options are subject to a time-based vesting schedule. Grant entries on Form 4 report $0.00 acquisition price for the awards (typical for new equity grants).

Key Details

• Transaction date: February 11, 2026; Form 4 filed February 13, 2026 (appears timely).
• Awards:
  • 71,900 RSUs (Footnotes F1–F2): each RSU converts to one share; RSUs vest 25% annually on Feb 1 of 2027, 2028, 2029 and 2030; no expiration date for RSUs per filing.
  • 107,850 stock options (Footnote F3): granted Feb 11, 2026; options vest in 16 substantially equal installments upon completion of each three full months of service following the grant date (i.e., quarterly over four years).
• Reported acquisition price on the Form 4 for both grants: $0.00 (grant reporting, not an open-market price).
• Shares owned following the transaction are not specified in the provided summary of the filing.
• No indication in the filing of a 10b5-1 plan, tax-withholding share surrender, or late filing note.

Context

• These are standard time-based grants to a CEO as compensation/incentive; RSUs represent a contingent future right to receive common shares, while the option awards will vest over time and require exercise to convert into shares. Grants do not by themselves indicate immediate buying or selling of stock by the insider.